Stockem, Chantal F. http://orcid.org/0000-0002-1782-5039
Galsky, Matthew D. http://orcid.org/0000-0001-7655-9378
van der Heijden, Michiel S. http://orcid.org/0000-0002-4407-7881
Article History
Accepted: 7 July 2023
First Online: 22 August 2023
Competing interests
: M.D.G. declares research funding from Janssen, Merk, Dendreon, Novartis, Bristol-Myers Squibb, AZ and Genentech/Roche; consulting fees from BioMotiv, Janssen, Merk, Dendreon, GlaxoSmithKline, Lilly, Astellas, Genetech, BMS, Novartis, Pfizer, EMD Serono, AZ, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals and NuMab; and stock from Rapt Therapeutics. M.S.v.d.H. declares the following competing interests: research funding from Bristol-Myers Squibb, AstraZeneca, Roche and 4SC; and consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seagen, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). C.F.S. declares no competing interests.